Norris Cotton Cancer Center, Geisel School of Medicine at Dartmouth, Lebanon, New Hampshire.
The Dartmouth Institute for Health Policy and Clinical Practice, Geisel School of Medicine at Dartmouth and White River Junction VA Medical Center, White River Junction, Vermont.
Cancer Epidemiol Biomarkers Prev. 2019 Apr;28(4):782-788. doi: 10.1158/1055-9965.EPI-18-0884. Epub 2019 Jan 30.
The high rate of non-muscle-invasive bladder cancer recurrence is a major challenge in patient management. miRNAs functionally regulate tumor cell proliferation and invasion, and have strong potential as biomarkers because they are robust to degradation. The objective of this project was to identify reproducible prognostic miRNAs in resected non-muscle-invasive bladder tumor tissue that are predictive of the recurrent tumor phenotype.
We utilized patients diagnosed with primary non-muscle-invasive bladder cancer in three independent cohorts for a biomarker discovery/validation approach. Baseline tumor tissue from patients with the clinically challenging, non-muscle-invasive primary low stage (Ta), high grade, and T1 tumors (tumors extending into the lamina propria) comprised the discovery cohort ( = 38). We isolated the tumor tissue RNA and assessed a panel of approximately 800 miRNAs.
miR-26b-5p was the top-ranking prognostic tumor tissue miRNA, with a time-to-recurrence HR 0.043 for levels above versus below median, ( = 0.0003). miR-26b-5p was related to a dose-response reduction in tumor recurrence, and levels above the median were also associated with reduced time-to-progression ( = 0.02). We used two independent longitudinal cohorts that included both low-grade and high-grade Ta and T1 tumors for validation and found a consistent relationship between miR-26b-5p and recurrence and progression.
Our results suggest that miR-26b-5p levels may be prognostic for non-muscle-invasive bladder cancer recurrence, and can feasibly be assessed in baseline tumor tissue from a wide variety of clinical settings.
Early identification of those non-muscle-invasive bladder tumor patients with refractory phenotypes would enable individualized treatment and surveillance.
非肌肉浸润性膀胱癌复发率高是患者管理的主要挑战。miRNAs 可在功能上调节肿瘤细胞的增殖和侵袭,并且具有作为生物标志物的强大潜力,因为它们不易降解。本项目的目的是在切除的非肌肉浸润性膀胱肿瘤组织中识别可重现的、预测复发性肿瘤表型的预后 miRNA。
我们利用三个独立队列中诊断为原发性非肌肉浸润性膀胱癌的患者进行了一项生物标志物发现/验证方法。具有临床挑战性的原发性非肌肉浸润性低分期(Ta)、高级别和 T1 肿瘤(肿瘤延伸至固有层)的患者的基线肿瘤组织构成了发现队列(=38)。我们分离肿瘤组织 RNA 并评估了大约 800 个 miRNA 的面板。
miR-26b-5p 是排名最高的预后肿瘤组织 miRNA,其水平高于或低于中位数的复发时间风险比(HR)为 0.043,(=0.0003)。miR-26b-5p 与肿瘤复发的剂量反应降低有关,且水平高于中位数也与进展时间缩短有关(=0.02)。我们使用包括低级别和高级别 Ta 和 T1 肿瘤的两个独立纵向队列进行验证,发现 miR-26b-5p 与复发和进展之间存在一致的关系。
我们的研究结果表明,miR-26b-5p 水平可能对非肌肉浸润性膀胱癌的复发具有预后意义,并且可以在广泛的临床环境中从基线肿瘤组织中进行评估。
早期识别那些具有难治性表型的非肌肉浸润性膀胱癌患者将能够实现个体化治疗和监测。